Owlstone Medical appoints Mark Capone to board of directors

Owlstone Medical (“OML”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the appointment of Mark Capone, former President and CEO of Myriad Genetics to its Board as an independent non-executive director. Following this appointment, the Owlstone Medical Board comprises seven members including one executive director and two independent non-executive directors.

We are excited to welcome Mark Capone to the Board at this important stage in our development. Mark is a recognized leader in the diagnostics industry who’s proven track record and deep commercial and corporate experience will be instrumental as we prepare to deploy Breath Biopsy into clinical settings for applications including lung cancer and liver disease.”

Billy Boyle, Co-Founder and CEO, Owlstone Medical

Mark is an accomplished 35-year life sciences executive, most recently serving as President and CEO of Myriad Genetics which he transformed from a pioneering start-up to one of the largest precision medicine companies in the world. During his 17-year tenure, the company developed and launched more than a dozen reimbursed molecular diagnostics achieving total annual revenues of more than $800 million. Prior to Myriad, he spent 17-years at Eli Lilly and Company in various positions across the entire value chain. Mark received a Bachelor of Science degree in Chemical Engineering from Penn State University graduating with highest distinction, and a Master of Science degree in (bio)Chemical Engineering and Master of Science in Management from Massachusetts Institute of Technology. He currently serves as President and CEO of Precision Medicine Advisors, LLC, is a non-executive board member of Abcam plc, Micoba Life Sciences Ltd., and NephroSant Inc.

“Owlstone Medical is poised to transform diagnostics through Breath Biopsy and I am very pleased to have been asked to help realize the vision of the team,” commented Mark Capone, non-executive director at Owlstone Medical. “I have been impressed with the potential of the platform, the progress made in high need clinical areas, and the passion and dedication of the leadership, and I look forward to helping drive the company’s success by supporting the development of their regulatory, reimbursement, and commercial strategy.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Owlstone Medical Ltd. (2023, June 05). Owlstone Medical appoints Mark Capone to board of directors. News-Medical. Retrieved on October 05, 2024 from https://www.news-medical.net/news/20210917/Owlstone-Medical-appoints-Mark-Capone-to-board-of-directors.aspx.

  • MLA

    Owlstone Medical Ltd. "Owlstone Medical appoints Mark Capone to board of directors". News-Medical. 05 October 2024. <https://www.news-medical.net/news/20210917/Owlstone-Medical-appoints-Mark-Capone-to-board-of-directors.aspx>.

  • Chicago

    Owlstone Medical Ltd. "Owlstone Medical appoints Mark Capone to board of directors". News-Medical. https://www.news-medical.net/news/20210917/Owlstone-Medical-appoints-Mark-Capone-to-board-of-directors.aspx. (accessed October 05, 2024).

  • Harvard

    Owlstone Medical Ltd. 2023. Owlstone Medical appoints Mark Capone to board of directors. News-Medical, viewed 05 October 2024, https://www.news-medical.net/news/20210917/Owlstone-Medical-appoints-Mark-Capone-to-board-of-directors.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Owlstone Medical Wins Contract from U.S. Department of Defense to Develop Handheld Breath Biopsy Device for Early Infectious Disease Detection